Arming antibodies: prospects and challenges for immunoconjugatesAnna M. Wu(University of California, Los Angeles), Peter D. Senter(Seagen (United States))Nature BiotechnologySeptember 1, 200510.1038/nbt1141Cited by 1,040SaveCiteExport RISWatch citationsAbstractRelated PapersApproval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.Peter Bross, Julie Beitz, Gang Chen et al.|PubMed|2001|861Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin ImmunoconjugateEric L. Sievers, F R Appelbaum, Ricardo Spielberger et al.|Blood|1999|456Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)–carbonyl complexRobert Waibel, Roger Alberto, Jörg Willuda et al.|Nature Biotechnology|1999|303Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial libraryRichard H. J. Beǵent, Marlies J. Verhaar, Kerry Chester et al.|Nature Medicine|1996|242Immunotoxins: magic bullets or misguided missiles?Ellen S. Vitetta, Philip E. Thorpe, Jonathan W. Uhr|Immunology Today|1993|209